{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T07:27:27Z","timestamp":1791098847593,"version":"4.1.0"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2012,5,4]],"date-time":"2012-05-04T00:00:00Z","timestamp":1336089600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0033743","type":"journal-article","created":{"date-parts":[[2012,5,4]],"date-time":"2012-05-04T18:37:18Z","timestamp":1336156638000},"page":"e33743","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cardiomyopathy and Response to Enzyme Replacement Therapy in a Male Mouse Model for Fabry Disease"],"prefix":"10.1371","volume":"7","author":[{"given":"Aurelie","family":"Nguyen Dinh Cat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Escoubet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Agrapart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violaine","family":"Griol-Charhbili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trenton","family":"Schoeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenguang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Jaimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Warnock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Jaisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,5,4]]},"reference":[{"key":"ref1","first-page":"3733","article-title":"Alpha-Galactosidase A deficiency: Fabry disease.","author":"RJ Desnick","year":"2001"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders.","volume":"281","author":"PJ Meikle","year":"1999","journal-title":"J Am Med Assoc"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening.","volume":"79","author":"M Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","article-title":"Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells.","volume":"95","author":"JS Shen","year":"2008","journal-title":"Mol Genet Metab"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1212\/01.wnl.0000247278.88077.09","article-title":"Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease.","volume":"67","author":"CR Kaneski","year":"2006","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy.","volume":"24","author":"R Schiffmann","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with fabry disease: natural history data from the fabry registry.","volume":"5","author":"C Wanner","year":"2010","journal-title":"Clin J Amer Soc Nephrol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jjcc.2007.12.001","article-title":"Terminal stage cardiac findings in patients with cardiac Fabry disease: An electrocardiographic, echocardiographic, and autopsy study.","volume":"51","author":"T Takenaka","year":"2008","journal-title":"J Cardiol"},{"key":"ref9","first-page":"1","article-title":"Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease.","volume":"2","author":"FC Fervenza","year":"2008","journal-title":"Biologics: Targets and Therapy"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1681\/ASN.2006121400","article-title":"Antiproteinuric therapy and Fabry nephropathy: Sustained reduction in proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.","volume":"18","author":"H Tahir","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/sj.ki.5002677","article-title":"Fabry disease: an underrecognized cause of proteinuria.","volume":"73","author":"FC Fervenza","year":"2008","journal-title":"Kidney intern"},{"key":"ref12","article-title":"Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.","author":"DG Warnock","year":"2011"},{"key":"ref13","article-title":"Fabry disease and the heart: an overview of the natural history and the effect of enzyme replacement therapy.","volume":"19\u201310","author":"JS Shah","year":"2005","journal-title":"Acta Paediatr Suppl 94: 11\u201314; discussion"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey.","volume":"28","author":"A Linhart","year":"2007","journal-title":"European Heart J"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy: Evidence for a Better Outcome With Early Treatment.","volume":"119","author":"F Weidemann","year":"2009","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1146\/annurev-med-090910-085119","article-title":"The fabry cardiomyopathy: models for the cardiologist.","volume":"62","author":"F Weidemann","year":"2011","journal-title":"Ann Rev Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1651-2227.2008.00700.x","article-title":"Cardiac manifestations of Anderson-Fabry disease in children and adolescents.","volume":"97","author":"C Kampmann","year":"2008","journal-title":"Acta Paediatr"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","article-title":"Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry.","volume":"64","author":"RJ Hopkin","year":"2008","journal-title":"Pediatr Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1542\/peds.2004-1678","article-title":"Pediatric Fabry disease.","volume":"115","author":"M Ries","year":"2005","journal-title":"Pediatrics"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1086\/316953","article-title":"Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice.","volume":"68","author":"YA Ioannou","year":"2001","journal-title":"Am J Hum Genet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"alpha-Galactosidase A deficient mice: a model of Fabry disease.","volume":"94","author":"T Ohshima","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/01.ASN.0000043901.45141.D4","article-title":"Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis.","volume":"14","author":"DT Eitzman","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/01.CIR.0000154550.15963.80","article-title":"Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency.","volume":"111","author":"PF Bodary","year":"2005","journal-title":"Circulation"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1440-1681.2008.04984.x","article-title":"Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect.","volume":"35","author":"JL Park","year":"2008","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref25","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2008111190","article-title":"Decreased Nitric Oxide Bioavailability in a Mouse Model of Fabry Disease.","author":"L Shu","year":"2009"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cjca.2010.12.035","article-title":"Myocardial alterations in the murine model of fabry disease can be reversed by enzyme replacement therapy.","volume":"27","author":"PA Rozenfeld","year":"2011","journal-title":"Canadian J Cardiol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/glycob\/cwj035","article-title":"Exploring the role of galectin 3 in kidney function: a genetic approach.","volume":"16","author":"M Bichara","year":"2006","journal-title":"Glycobiology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1096\/fj.07-8357com","article-title":"Conditional glucocorticoid receptor expression in the heart induces atrio-ventricular block.","volume":"21","author":"Y Sainte-Marie","year":"2007","journal-title":"FASEB J"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1161\/CIRCULATIONAHA.105.533778","article-title":"Temporally controlled onset of dilated cardiomyopathy through disruption of the SRF gene in adult heart.","volume":"112","author":"A Parlakian","year":"2005","journal-title":"Circulation"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF00788278","article-title":"Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light.","volume":"89","author":"P Whittaker","year":"1994","journal-title":"Basic Res Cardiol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1161\/CIRCULATIONAHA.104.503706","article-title":"Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias.","volume":"111","author":"A Ouvrard-Pascaud","year":"2005","journal-title":"Circulation"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cardiores.2004.06.006","article-title":"Matricellular proteins in the heart: possible role during stress and remodeling.","volume":"64","author":"MW Schellings","year":"2004","journal-title":"Cardiovas Res"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"D715","DOI":"10.1093\/nar\/gkm728","article-title":"EuroPhenome and EMPReSS: online mouse phenotyping resource.","volume":"36","author":"AM Mallon","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"H1829","DOI":"10.1152\/ajpheart.00224.2002","article-title":"Morphometry and strain distribution of the C57BL\/6 mouse aorta.","volume":"283","author":"X Guo","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1681\/ASN.2005040383","article-title":"An in vitro model of Fabry disease.","volume":"16","author":"L Shu","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/eurheartj\/ehp426","article-title":"Aortic remodelling in Fabry disease.","volume":"31","author":"F Barbey","year":"2010","journal-title":"Eur Heart J"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.hlc.2007.03.007","article-title":"Cardiovascular manifestations in Fabry disease: a clinical and echocardiographic study.","volume":"16","author":"N Sadick","year":"2007","journal-title":"Heart Lung Circ"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.2353\/ajpath.2008.070576","article-title":"Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease.","volume":"172","author":"C Chimenti","year":"2008","journal-title":"Am J Pathol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijcard.2008.04.075","article-title":"Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy.","volume":"132","author":"R Toro","year":"2009","journal-title":"Int J Cardiol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.amjcard.2005.05.033","article-title":"Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease.","volume":"96","author":"JS Shah","year":"2005","journal-title":"Am J Cardiol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey.","volume":"46","author":"A Mehta","year":"2009","journal-title":"J Med Genet"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry.","volume":"11","author":"S Waldek","year":"2009","journal-title":"Genet Med"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijcard.2003.10.065","article-title":"Atrioventricular conduction disturbances in a young patient with Fabry\u2019s disease without other signs of cardiac involvement.","volume":"99","author":"NT Kouris","year":"2005","journal-title":"Int J Cardiol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0735-1097(02)02713-4","article-title":"Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy.","volume":"41","author":"I Olivotto","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1159\/000087675","article-title":"Cardiopulmonary exercise testing in Fabry disease.","volume":"72","author":"G Bierer","year":"2005","journal-title":"Respiration"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1445-5994.2008.01669.x","article-title":"Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement.","volume":"38","author":"T Lobo","year":"2008","journal-title":"Intern Med J"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacc.2009.09.045","article-title":"Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation.","volume":"55","author":"CT Tsai","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"e15033","DOI":"10.1371\/journal.pone.0015033","article-title":"Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.","volume":"5","author":"J Marshall","year":"2010","journal-title":"PLoS One"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0033743","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T04:10:33Z","timestamp":1561695033000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0033743"}},"subtitle":[],"editor":[{"given":"Raphael","family":"Schiffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,5,4]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2012,5,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0033743","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,4]]}}}